JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723 [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Pharmaceutical to develop, manufacture and commercialize the latter's STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD). The licensing deal for Kaken's STAT6 program includes global rights to its lead candidate, KP-723. How the Licensing Deal for the AD Program Benefits JNJ The licensing deal with Kaken reinforces Johnson & Johnson's dedication to targeting disease-specific pathways across diverse patient populations, leveraging innovative mechanisms and approaches to revolutionize the treatment of AD and other autoimmune and allergic conditions. Per JNJ, most AD patients fail to achieve remission with currently available treatments, representing a huge unmet medical need. The company believes that the STAT6 program stands out as a promising research area, offering the potential for a safe and effective novel oral therapy for those suffering from AD and other autoimmune diseases. In the past three months, shares of JNJ have lost 10.2% compare
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- FDA proposes new tests to detect asbestos in cosmetics and other products containing talc [CBS News]CBS News
- 8 changes following NBC News' reporting on unclaimed bodies used for medical research [MSNBC.com]MSNBC.com
- US FDA proposes standardized testing to detect asbestos in talc products [CNN]CNN
- US FDA proposes standardized testing to detect asbestos in talc products [CNN]CNN
- FDA proposes new testing rules to ensure cosmetics are asbestos-free [Yahoo! Finance Canada]Yahoo! Finance Canada
JNJ
Earnings
- 10/15/24 - Beat
JNJ
Sec Filings
- 12/12/24 - Form 4
- 12/12/24 - Form 4
- 12/12/24 - Form 4
- JNJ's page on the SEC website